Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising its annual revenue and earnings guidance for the year. The pharmaceutical giant, known for its blockbuster COVID-19 products, is now forging ahead with a diversified growth strategy, reflecting a well-balanced portfolio of oncology, cardiology, and other in-demand […]
Pfizer has obtained approval for PAXLOVID, an oral combination therapy of nirmatrelvir tablets and ritonavir tablets, from the US Food and Drug Administration (FDA) to treat adult patients with mild-to-moderate COVID-19 who are at a high risk of hospitalization or death. PAXLOVID has been available in the US since December 2021 under Emergency Use Authorization […]
Torrent Pharmaceuticals has entered into a licensing agreement with Medicine Patent Pool (MPP) for manufacturing and commercializing the generic version of Pfizer’s oral Covid-19 treatment. Pfizer’s oral Covid-19 treatment is made up of PAXLOVID (nirmatrelvir), which inhibits a SARS-CoV-2 protein to prevent the SARSCoV-2 virus from replicating and ritonavir, which slows down the breakdown of […]
SMS Pharmaceuticals has secured a non‐exclusive license via the Medicines Patent Pool (MPP) for manufacturing nirmatrelvir, an oral antiviral Covid‐19 drug developed by Pfizer, to increase wider access to treatment in 95 low‐ and middle‐ income countries. Previously, Pfizer had announced that the clinical trial of PAXLOVID (nirmatrelvir tablets and ritonavir tablets) demonstrated significant reduction […]